Nuvalent (NUVL) Income towards Parent Company (2020 - 2026)
Nuvalent's (NUVL) quarterly Income towards Parent Company came in at -$109.3 million in Q1 2026, down 29.2% YoY from -$154.3 million in Q1 2025, and down 277.94% on a QoQ basis from -$28.9 million in Q4 2025.
Analysis
Nuvalent (NUVL) Income towards Parent Company (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Income towards Parent Company data on file, last reported at -$109.3 million in Q1 2026.
- Quarterly Income towards Parent Company fell 29.2% year-over-year to -$109.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$360.3 million (down 19.75% YoY) and the FY2025 annual result came in at -$335.6 million, down 28.7% from the prior year.
- Income towards Parent Company eased to -$109.3 million in Q1 2026, from -$28.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$18.6 million in Q1 2022 to a low of -$122.4 million in Q3 2025.
- A 5-year average of -$54.0 million and a median of -$38.3 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company sank 201.38% — and 2025, when it soared 61.33%.
- Tracing NUVL's Income towards Parent Company over 5 years: stood at -$27.5 million in 2022, then sank by 39.44% to -$38.3 million in 2023, then sank by 95.24% to -$74.8 million in 2024, then soared by 61.33% to -$28.9 million in 2025, then slumped by 277.94% to -$109.3 million in 2026.
- The last three Income towards Parent Company figures came in at -$109.3 million (Q1 2026), -$28.9 million (Q4 2025), and -$122.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -109.28 Mn |
| Dec 31, 2025 | -28.91 Mn |
| Sep 30, 2025 | -122.44 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -74.80 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -26.08 Mn |
| Sep 30, 2022 | -19.72 Mn |
| Jun 30, 2022 | -18.47 Mn |
| Mar 31, 2022 | -17.55 Mn |
| Dec 31, 2021 | -17.26 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |